Equine gastric disease treatment sharpens around diagnosis and subtype

Equine gastric disease treatment is moving further away from one-size-fits-all care. A recent The Horse clinical explainer highlights a now-familiar but still important point for practitioners: treatment should start with an accurate diagnosis and then combine pharmacologic therapy with management changes tailored to the horse’s lesion type and risk factors. That message aligns with the evidence base around equine gastric ulcer syndrome, which has increasingly separated squamous and glandular disease into distinct clinical problems rather than treating both as interchangeable “ulcers.” (thehorse.com)

That distinction matters because the field’s understanding of EGUS has evolved over the past decade. The 2015 European College of Equine Internal Medicine consensus statement established gastroscopy as the only reliable antemortem diagnostic method and emphasized that the presence of equine squamous gastric disease, or ESGD, does not predict equine glandular gastric disease, or EGGD, and vice versa. More recent reviews have reinforced that EGGD is often harder to treat, less well understood mechanistically, and more dependent on addressing stress, exercise intensity, housing, and feeding practices in parallel with drug therapy. (pmc.ncbi.nlm.nih.gov)

On the pharmacology side, omeprazole remains the anchor drug, especially for ESGD. In the U.S., Boehringer Ingelheim’s GASTROGARD is labeled by the FDA for treatment and prevention of recurrence of gastric ulcers in horses and foals 4 weeks of age and older, with treatment dosing at 4 mg/kg and recurrence-prevention dosing at 2 mg/kg. That regulatory status still matters in practice, especially given FDA scrutiny of unapproved omeprazole products marketed for horses. At the same time, published reviews and consensus-derived recommendations suggest that glandular disease may require protocols such as omeprazole plus sucralfate, or misoprostol-based treatment in selected cases, rather than relying on omeprazole alone. (animalhealth.boehringer-ingelheim.com)

The evidence on adjuncts is more mixed. One of the newer studies cited in your source set, published in Equine Veterinary Journal in early 2025, tested a nutraceutical containing lecithin, pectin, and meadowsweet after omeprazole treatment in a blinded, randomized, placebo-controlled trial of 30 horses. The product did not significantly prevent recurrence of ESGD or EGGD on follow-up gastroscopy, although the investigators reported changes in salivary biomarkers that may suggest effects on gastric mucosal health. In practical terms, that suggests some supplements may have biologic signals worth exploring, but they haven’t displaced endoscopic reassessment and standard pharmacologic care. (pubmed.ncbi.nlm.nih.gov)

Other recent literature also reinforces how difficult diagnosis can be without scoping. The ECEIM consensus noted there are no reliable hematologic or biochemical markers that can replace gastroscopy, and newer behavioral research suggests many horses may not show classic physical signs until disease is advanced. That dovetails with retrospective work, including the Veterinary Sciences paper in your source set, indicating that lesion location and presentation don’t always map neatly onto obvious clinical signs. For practitioners, that means poor performance, attitude changes, girthing issues, intermittent colic, or appetite shifts still need careful differential workups rather than empiric ulcer treatment alone. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this is less about a new drug launch than about a treatment framework that continues to sharpen. The practical takeaway is to separate ESGD from EGGD early, use gastroscopy whenever feasible, set expectations with pet parents that management changes are part of treatment, and be cautious about overpromising on supplements or empiric protocols. It also highlights a persistent gap in equine pharmacology: while omeprazole is well established and FDA-labeled for gastric ulcers broadly, the literature repeatedly points to lower and less predictable success in glandular disease, creating demand for better-supported alternatives and clearer treatment algorithms. (pmc.ncbi.nlm.nih.gov)

There are also regulatory and welfare angles worth watching. Industry discussion over withholding omeprazole around race day has underscored concern that stopping acid suppression, even briefly, may affect horses with active or recently treated disease. Meanwhile, emerging research is exploring alternatives such as long-acting injectable omeprazole in some settings and even newer acid suppressants like vonoprazan, though those approaches are not yet standard U.S. practice and need more clinical outcome data. (yahoo.com)

What to watch: The next phase of this story will likely center on better evidence for EGGD-specific protocols, recurrence prevention after standard omeprazole courses, and whether newer acid-suppressing agents or delivery methods can improve outcomes beyond what current labeled therapy and management changes achieve. (pubmed.ncbi.nlm.nih.gov)